Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis
✍ Scribed by Nitin Kapur; Ian B. Masters; Peter S. Morris; John Galligan; Robert Ware; Anne B. Chang
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 84 KB
- Volume
- 47
- Category
- Article
- ISSN
- 8755-6863
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Rationale
Exacerbations in non‐cystic fibrosis (CF) bronchiectasis are associated with worsening lung functions and quality of life. A standardized definition of exacerbation could improve clinical care and research.
Objective
To formulate a clinically useful definition of pulmonary exacerbation for pediatric non‐CF bronchiectasis.
Methods
A cohort of 69 children with non‐CF bronchiectasis was prospectively followed for 900 child‐months. The changes in clinical, systemic, and lung function parameters from 81 exacerbations were statistically evaluated using conditional logistic regression, receiver operating characteristic, sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) to formulate a definition of a pulmonary exacerbation. Formation of major and minor criteria was statistically based and models were developed.
Measurements and Main Results
Wet cough and cough severity (score ≥2) over 72‐hr were the best predictors of an exacerbation with area under the curve (AUC) of 0.85 (95% CI 0.79–0.92) and 0.84 (95% CI 0.77–0.91), respectively. Sputum color, chest pain, dyspnea, hemoptysis, and chest signs were significant though minor criteria. Inclusion of serum C‐reactive protein, amyloid‐A, and IL6 to the definition improved its specificity and PPV. Our final combined model consisted of one major with one investigatory criterion (PPV 91%, NPV 72%); two major criteria (PPV 79%, NPV 91%); or one major and two minor criteria (PPV 79%, NPV 94%).
Conclusions
Pulmonary exacerbation in children with non‐CF bronchiectasis can be validly predicted using a standardized assessment of clinical features, with additional systemic markers improving predictive values. This definition potentially facilitates earlier detection (leading to appropriate management) of exacerbations. Pediatr Pulmonol. 2012; 47:68–75. © 2010 Wiley Periodicals, Inc.
📜 SIMILAR VOLUMES
## Background: Night-time symptoms and hypoxemia during sleep may affect sleep quality in children with chronic lung disease such as bronchiectasis. poor sleep quality may impair growth, learning, and emotional development of children. our aim was to assess the sleep quality and associated factors
SUMMARY. In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function. Only stable patients with pancreatic insufficiency wer
## Abstract ## Background Gastro‐esophageal reflux (GOR) may contribute to lung disease in children with cystic fibrosis (CF). There is conflicting evidence regarding the effect of chest physiotherapy (CPT) in the head‐down position on GOR. Furthermore, there is currently no evidence on the impact